Several studies have demonstrated the ability of this agent to inhibit proliferation of poorly differentiated thyroid cancer cell lines with and without BRAF V600E mutations in vitro (Ouyang et al, 2006; Salvatore et al, 2006). This evidence concerns the gene BRAF and thyroid cancer.